Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.11.23 | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 | 179 | GlobeNewswire (Europe) | - New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone - - Excess aldosterone... ► Artikel lesen | |
11.11.23 | Esperion Therapeutics, Inc.: Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 | 312 | GlobeNewswire (Europe) | - Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis - ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE)... ► Artikel lesen | |
11.11.23 | Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association | 199 | GlobeNewswire (Europe) | Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing... ► Artikel lesen | |
11.11.23 | Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine | 194 | GlobeNewswire (Europe) | Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity... ► Artikel lesen | |
11.11.23 | Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination | 376 | GlobeNewswire (Europe) | NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Apollo Strategic Growth Capital II (NYSE: APGB) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will liquidate... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
GAMESTOP | 489 |
EVOTEC | 438 |
TUI | 335 |
NVIDIA | 280 |
BAYER | 252 |
DEUTSCHE BANK | 248 |
PLUG POWER | 235 |
NEL | 227 |
RHEINMETALL | 206 |
SIEMENS ENERGY | 187 |
COMMERZBANK | 176 |
BARRICK GOLD | 160 |
TESLA | 160 |
VOLKSWAGEN | 150 |
RWE | 149 |
BYD | 148 |
BASF | 147 |
DEUTSCHE LUFTHANSA | 139 |
ALLIANZ | 134 |
DEUTSCHE TELEKOM | 133 |
MERCEDES-BENZ | 126 |
RENK GROUP | 119 |
ALIBABA | 118 |
E.ON | 114 |
REDCARE PHARMACY | 112 |